Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $11.00 at Wells Fargo & Company

Inozyme Pharma (NASDAQ:INZY) had its price target reduced by Wells Fargo & Company from $14.00 to $11.00 in a research report report published on Monday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research analysts also recently weighed in on the company. Wedbush restated an “outperform” rating and set a $12.00 target price on shares of Inozyme Pharma in a research note on Friday. Piper Sandler dropped their price target on Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday. Raymond James initiated coverage on shares of Inozyme Pharma in a research report on Thursday, December 12th. They issued an “outperform” rating and a $26.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Finally, HC Wainwright upped their price target on shares of Inozyme Pharma from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $18.33.

Inozyme Pharma Stock Performance

INZY stock opened at $1.72 on Monday. The firm has a 50-day simple moving average of $2.96 and a two-hundred day simple moving average of $4.36. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.68 and a current ratio of 7.68. Inozyme Pharma has a one year low of $1.61 and a one year high of $7.80. The firm has a market cap of $110.49 million, a price-to-earnings ratio of -1.10 and a beta of 1.35.

Inozyme Pharma (NASDAQ:INZY) last announced its earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05. On average, equities analysts forecast that Inozyme Pharma will post -1.59 EPS for the current fiscal year.

Institutional Trading of Inozyme Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Eventide Asset Management LLC lifted its position in Inozyme Pharma by 5.0% during the third quarter. Eventide Asset Management LLC now owns 4,134,436 shares of the company’s stock valued at $21,623,000 after purchasing an additional 198,216 shares during the period. Samlyn Capital LLC raised its stake in shares of Inozyme Pharma by 15.0% during the 2nd quarter. Samlyn Capital LLC now owns 3,350,535 shares of the company’s stock valued at $14,943,000 after buying an additional 437,622 shares during the last quarter. State Street Corp lifted its holdings in shares of Inozyme Pharma by 5.0% in the 3rd quarter. State Street Corp now owns 1,050,420 shares of the company’s stock valued at $5,494,000 after buying an additional 50,386 shares during the period. Geode Capital Management LLC boosted its stake in shares of Inozyme Pharma by 1.7% in the third quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock worth $6,126,000 after buying an additional 19,499 shares during the last quarter. Finally, Barclays PLC grew its holdings in Inozyme Pharma by 261.4% during the third quarter. Barclays PLC now owns 76,730 shares of the company’s stock worth $401,000 after acquiring an additional 55,497 shares during the period. Institutional investors and hedge funds own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.